Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis (original) (raw)
This paper analyzes the cost-utility of tumor necrosis factor-alpha (TNF-a) inhibitors in the treatment of rheumatoid arthritis (RA). RA, a chronic autoimmune disease affecting millions, often leads to significant economic burdens and reduced quality of life. The study evaluates multiple treatment strategies, including various combinations of biologic and non-biologic disease-modifying anti-rheumatic drugs (DMARDs), by presenting incremental cost-effectiveness ratios (ICERs) based on treatment outcomes such as achieving ACR criteria and probabilities of remission. Key findings illustrate the varying impact of each treatment regimen on both costs and quality-adjusted life years (QALYs), guiding healthcare decision-makers in selecting optimal RA therapies.